Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 7, Pages 1349-1350Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdw138
Keywords
-
Categories
Ask authors/readers for more resources
We report the results of the first prospective clinical trial testing a Hh inhibitor (Vismodegib) in patients with lymphoma or CLL. Despite frequent Hh pathway activation and good bioavailability, treatment with vismodegib did not show significant clinical efficacy in patients with lymphoma nor CLL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
